The human trial of Bharat Biotech's anti-Covid-19 vaccine Covaxin began at Rohtak's Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij tweeted. "Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects," Vij further said in his tweet. Read more.
The government has identified 1,377 fraudulent exporters who have claimed refunds amounting to Rs 1,875 crore under integrated goods and services tax (IGST). As on date, 7,516 exporters are in the risky exporter list, they added. Out of them, IGST
refund worth Rs 1,363 crore is suspended in respect of 2,830 risky exporters. Read more.
Union Defence Minister Rajnath Singh on Friday assured that not an inch of our land can be taken by any power in the world while he interacted with the Indian Army and ITBP personnel at Lukung. Emphasising on finding a diplomatic solution to the standoff, he further said, "If a solution can be found by talks, there is nothing better." Read more.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.